抗磷脂综合征患者血栓复发的危险因素——单中心队列研究

IF 1.8
TH open : companion journal to thrombosis and haemostasis Pub Date : 2025-07-18 eCollection Date: 2025-01-01 DOI:10.1055/a-2646-9016
Natali Karandyszowska, Francesca Faustini, Hevgin Alagündüz, Jacob Widaeus, Felicia Carlens, Ann-Louise Jensen, Anna Oksanen, Maria Magnusson, Iva Gunnarsson, Elisabet Svenungsson, Aleksandra Antovic, Maria Bruzelius
{"title":"抗磷脂综合征患者血栓复发的危险因素——单中心队列研究","authors":"Natali Karandyszowska, Francesca Faustini, Hevgin Alagündüz, Jacob Widaeus, Felicia Carlens, Ann-Louise Jensen, Anna Oksanen, Maria Magnusson, Iva Gunnarsson, Elisabet Svenungsson, Aleksandra Antovic, Maria Bruzelius","doi":"10.1055/a-2646-9016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recurrent thrombosis poses a clinical challenge in patients with antiphospholipid syndrome (APS). There are limited data on risk factors due to its rarity.</p><p><strong>Aims: </strong>This study aimed to study the association between cardiovascular (CV) and APS-related risk factors and recurrent thrombosis and evaluate the adjusted Global Anti-Phospholipid Syndrome Score (aGAPSS).</p><p><strong>Methods: </strong>This retrospective cohort study comprised APS patients at Karolinska University Hospital, Sweden, from 2014 to 2020 with follow-up until the last medical visit or death. Multiple thrombotic events per patient were included. Cox proportional hazard model estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Logistic regression and Poisson regression were conducted to further examine the relation between risk factors and recurrent thrombosis.</p><p><strong>Results: </strong>The cohort included 250 patients (67% women and 52% primary APS) with a median age of 44.5 (35-59) years. Forty-nine recurrent thrombotic events occurred in 36 patients, yielding an incidence of 4.46 (95% CI 3.30-5.90) per 100 person-years. Thrombocytopenia was associated with recurrent thrombosis (HR 2.57 [95% CI 1.01-6.02]). Although CV risk factors were not consistently significant for recurrent thrombosis, chronic kidney disease (CKD) indicated an increased probability (OR 2.55 [95% CI 1.01-6.26]). For each point of aGAPSS, the HR for recurrent thrombosis increased by 10% (1.10 [95% CI 1.01-1.19]). Notably, inadequate anticoagulation triggered recurrence in almost a quarter of cases.</p><p><strong>Conclusion: </strong>Thrombocytopenia was confirmed as a major risk factor for recurrent thrombosis. CKD warrants closer attention in future assessment. Although an increase in aGAPSS was associated with recurrent thrombosis, further evaluation is required. Improving anticoagulation treatment is essential to reduce recurrence.</p>","PeriodicalId":94220,"journal":{"name":"TH open : companion journal to thrombosis and haemostasis","volume":"9 ","pages":"a26469016"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303155/pdf/","citationCount":"0","resultStr":"{\"title\":\"Risk Factors for Recurrent Thrombosis in Patients with Antiphospholipid Syndrome-A Single-Centre Cohort Study.\",\"authors\":\"Natali Karandyszowska, Francesca Faustini, Hevgin Alagündüz, Jacob Widaeus, Felicia Carlens, Ann-Louise Jensen, Anna Oksanen, Maria Magnusson, Iva Gunnarsson, Elisabet Svenungsson, Aleksandra Antovic, Maria Bruzelius\",\"doi\":\"10.1055/a-2646-9016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Recurrent thrombosis poses a clinical challenge in patients with antiphospholipid syndrome (APS). There are limited data on risk factors due to its rarity.</p><p><strong>Aims: </strong>This study aimed to study the association between cardiovascular (CV) and APS-related risk factors and recurrent thrombosis and evaluate the adjusted Global Anti-Phospholipid Syndrome Score (aGAPSS).</p><p><strong>Methods: </strong>This retrospective cohort study comprised APS patients at Karolinska University Hospital, Sweden, from 2014 to 2020 with follow-up until the last medical visit or death. Multiple thrombotic events per patient were included. Cox proportional hazard model estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Logistic regression and Poisson regression were conducted to further examine the relation between risk factors and recurrent thrombosis.</p><p><strong>Results: </strong>The cohort included 250 patients (67% women and 52% primary APS) with a median age of 44.5 (35-59) years. Forty-nine recurrent thrombotic events occurred in 36 patients, yielding an incidence of 4.46 (95% CI 3.30-5.90) per 100 person-years. Thrombocytopenia was associated with recurrent thrombosis (HR 2.57 [95% CI 1.01-6.02]). Although CV risk factors were not consistently significant for recurrent thrombosis, chronic kidney disease (CKD) indicated an increased probability (OR 2.55 [95% CI 1.01-6.26]). For each point of aGAPSS, the HR for recurrent thrombosis increased by 10% (1.10 [95% CI 1.01-1.19]). Notably, inadequate anticoagulation triggered recurrence in almost a quarter of cases.</p><p><strong>Conclusion: </strong>Thrombocytopenia was confirmed as a major risk factor for recurrent thrombosis. CKD warrants closer attention in future assessment. Although an increase in aGAPSS was associated with recurrent thrombosis, further evaluation is required. Improving anticoagulation treatment is essential to reduce recurrence.</p>\",\"PeriodicalId\":94220,\"journal\":{\"name\":\"TH open : companion journal to thrombosis and haemostasis\",\"volume\":\"9 \",\"pages\":\"a26469016\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303155/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"TH open : companion journal to thrombosis and haemostasis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2646-9016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"TH open : companion journal to thrombosis and haemostasis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2646-9016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:复发性血栓形成是抗磷脂综合征(APS)患者的临床挑战。由于罕见,有关风险因素的数据有限。目的:本研究旨在研究心血管(CV)和aps相关危险因素与血栓复发的相关性,并评估调整后的全球抗磷脂综合征评分(aGAPSS)。方法:本回顾性队列研究纳入2014 - 2020年在瑞典卡罗林斯卡大学医院就诊的APS患者,随访至最后一次就诊或死亡。每位患者包括多个血栓事件。Cox比例风险模型估计了风险比(hr)和95%置信区间(ci)。采用Logistic回归和泊松回归进一步分析危险因素与血栓复发的关系。结果:该队列包括250例患者(67%为女性,52%为原发性APS),中位年龄为44.5(35-59)岁。36例患者发生49例复发性血栓事件,发生率为4.46 (95% CI 3.30-5.90) / 100人年。血小板减少与血栓复发相关(HR 2.57 [95% CI 1.01-6.02])。虽然心血管危险因素对复发性血栓的影响并不一致,但慢性肾脏疾病(CKD)的发生率增加(OR 2.55 [95% CI 1.01-6.26])。每增加一个aGAPSS点,血栓复发的HR增加10% (1.10 [95% CI 1.01-1.19])。值得注意的是,抗凝治疗不足导致近四分之一的病例复发。结论:血小板减少是血栓复发的主要危险因素。CKD在未来的评估中值得密切关注。虽然aGAPSS升高与血栓复发有关,但仍需进一步评估。改善抗凝治疗对减少复发至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Risk Factors for Recurrent Thrombosis in Patients with Antiphospholipid Syndrome-A Single-Centre Cohort Study.

Risk Factors for Recurrent Thrombosis in Patients with Antiphospholipid Syndrome-A Single-Centre Cohort Study.

Risk Factors for Recurrent Thrombosis in Patients with Antiphospholipid Syndrome-A Single-Centre Cohort Study.

Risk Factors for Recurrent Thrombosis in Patients with Antiphospholipid Syndrome-A Single-Centre Cohort Study.

Background: Recurrent thrombosis poses a clinical challenge in patients with antiphospholipid syndrome (APS). There are limited data on risk factors due to its rarity.

Aims: This study aimed to study the association between cardiovascular (CV) and APS-related risk factors and recurrent thrombosis and evaluate the adjusted Global Anti-Phospholipid Syndrome Score (aGAPSS).

Methods: This retrospective cohort study comprised APS patients at Karolinska University Hospital, Sweden, from 2014 to 2020 with follow-up until the last medical visit or death. Multiple thrombotic events per patient were included. Cox proportional hazard model estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Logistic regression and Poisson regression were conducted to further examine the relation between risk factors and recurrent thrombosis.

Results: The cohort included 250 patients (67% women and 52% primary APS) with a median age of 44.5 (35-59) years. Forty-nine recurrent thrombotic events occurred in 36 patients, yielding an incidence of 4.46 (95% CI 3.30-5.90) per 100 person-years. Thrombocytopenia was associated with recurrent thrombosis (HR 2.57 [95% CI 1.01-6.02]). Although CV risk factors were not consistently significant for recurrent thrombosis, chronic kidney disease (CKD) indicated an increased probability (OR 2.55 [95% CI 1.01-6.26]). For each point of aGAPSS, the HR for recurrent thrombosis increased by 10% (1.10 [95% CI 1.01-1.19]). Notably, inadequate anticoagulation triggered recurrence in almost a quarter of cases.

Conclusion: Thrombocytopenia was confirmed as a major risk factor for recurrent thrombosis. CKD warrants closer attention in future assessment. Although an increase in aGAPSS was associated with recurrent thrombosis, further evaluation is required. Improving anticoagulation treatment is essential to reduce recurrence.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信